Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. L-Lysine increased the cytotoxicity effect of doxorubicin in MDA-MB-231 and MDA-MB-468 breast cancer cell lines

    Publikation: Bidrag til tidsskriftKonferenceartikelForskningpeer review

  2. TSGA10 and H2AX competition over binding HIF-1 in breast cancer

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  3. Human endogenous retroviruses and their implication for immunotherapeutics of cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Very Early Response Evaluation by PET/MR in Patients with Lung Cancer-Timing and Feasibility

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Early initiated postoperative rehabilitation reduces fatigue in patients with operable lung cancer: A randomized trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Medicinsk behandling af lungecancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Abir Salwa Ali
  • Malin Grönberg
  • Seppo W Langer
  • Morten Ladekarl
  • Geir Olav Hjortland
  • Lene Weber Vestermark
  • Pia Österlund
  • Staffan Welin
  • Henning Grønbæk
  • Ulrich Knigge
  • Halfdan Sorbye
  • Eva Tiensuu Janson
Vis graf over relationer

High-grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs, G3) are aggressive cancers of the digestive system with poor prognosis and survival. Platinum-based chemotherapy (cisplatin/carboplatin + etoposide) is considered the first-line palliative treatment. Etoposide is frequently administered intravenously; however, oral etoposide may be used as an alternative. Concerns for oral etoposide include decreased bioavailability, inter- and intra-patient variability and patient compliance. We aimed to evaluate possible differences in progression-free survival (PFS) and overall survival (OS) in patients treated with oral etoposide compared to etoposide given as infusion. Patients (n = 236) from the Nordic NEC study were divided into three groups receiving etoposide as a long infusion (24 h, n = 170), short infusion (≤ 5 h, n = 33) or oral etoposide (n = 33) according to hospital tradition. PFS and OS were analyzed with Kaplan-Meier (log-rank), cox proportional hazard ratios and confidence intervals. No statistical differences were observed in PFS or OS when comparing patients receiving long infusion (median PFS 3.8 months, median OS 14.5 months), short infusion (PFS 5.6 months, OS 11.0 months) or oral etoposide (PFS 5.4 months, OS 11.3 months). We observed equal efficacy for the three administration routes suggesting oral etoposide may be safe and efficient in treating high-grade GEP-NEN, G3 patients scheduled for cisplatin/carboplatin + etoposide therapy.

OriginalsprogEngelsk
TidsskriftAnnals of Oncology
Vol/bind35
Udgave nummer4
Sider (fra-til)47
ISSN0923-7534
DOI
StatusUdgivet - 6 mar. 2018

ID: 56463415